Impact of PTBP1 rs11085226 on glucose-stimulated insulin release in adult Danes

BMC Medical Genetics

Anette P Gjesing⁷  Torben Hansen¹  Oluf Pedersen⁷  Cramer Christensen³  Ivan Brandslund⁵  Torsten Lauritzen⁴  Marit Eika Jørgensen⁶  Torben Jørgensen²  Henrik Vestergaard⁷  Tue H Hansen⁷ 

[1] Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark;Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark;Department of Internal Medicine and Endocrinology, SLB, Vejle Hospital, Kabbeltoft 25, Vejle, DK-7100, Denmark;Department of Public Health, Section of General Practice, Aarhus University, Bartholins Allé 2, Aarhus, DK-8000, Denmark;Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark;Steno Diabetes Center, Niels Steensens Vej 2, Gentofte, DK-2820, Denmark;The Novo Nordisk Foundation Center for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 1, Copenhagen, DK-2100, Denmark

关键词: Insulin release;    Genetics;    Beta-cell function;    Type 2 diabetes;    Polypyrimidine tract binding protein 1;   

Others  :  1171794
DOI  :  10.1186/s12881-015-0160-7

 received in 2014-09-09, accepted in 2015-02-26,  发布年份 2015

【 摘 要 】

Background

The variant rs11085226 (G) within the gene encoding polypyrimidine tract binding protein 1 (PTBP1) was reported to associate with reduced insulin release determined by an oral glucose tolerance test (OGTT) as well as an intravenous glucose tolerance test (IVGTT). The aim of the present study was to validate the association of the rs11085226 G-allele of PTBP1 with previously investigated OGTT- and IVGTT-derived diabetes-related metabolic quantitative phenotypes, to conduct exploratory analyses of additional measures of beta-cell function, and to further investigate a potential association with type 2 diabetes.

Methods

PTBP1 rs11085226 was genotyped in 20,911 individuals of Danish Caucasian ethnicity ascertained from 9 study samples. Case control analysis was performed on 5,634 type 2 diabetic patients and 11,319 individuals having a normal fasting glucose level as well as 4,641 glucose tolerant controls, respectively. Quantitative trait analyses were performed in up to 13,605 individuals subjected to an OGTT or blood samples obtained after an overnight fast, as well as in 596 individuals subjected to an IVGTT.

Results

Analyses of fasting and OGTT-derived quantitative traits did not show any significant associations with the PTBP1 rs11085226 variant. Meta-analysis of IVGTT-derived quantitative traits showed a nominally significant association between the variant and reduced beta-cell responsiveness to glucose (β = −0.1 mmol · kg⁻¹ · min⁻¹; 95% CI: −0.200.20 – −0.024; P = 0.01) assuming a dominant model of inheritance, but failed to replicate a previously reported association with area under the curve (AUC) for insulin. Case control analysis did not show an association of the PTBP1 rs11085226 variant with type 2 diabetes.

Conclusions

Despite failure to replicate the previously reported associations of PTBP1 rs11085226 with OGTT- and IVGTT-derived measures of beta-cell function, we did find a nominally significant association with reduced beta-cell responsiveness to glucose during an IVGTT, a trait not previously investigated, leaving the potential influence of this variant in PTBP1 on glucose stimulated insulin release open for further investigation. However, the present study does not support the hypothesis that the variant confers risk of type 2 diabetes.

【 授权许可】

   
2015 Hansen et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Shaw JE, Sicree RA, Zimmet PZ: Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010, 87(1):4-14.
• [2]Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet, 365(9467):1333–46.
• [3]DeFronzo RA: Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 2004, 88(4):787-835.
• [4]Poulsen P, Kyvik KO, Vaag A, Beck-Nielsen H: Heritability of type II (non-insulin-dependent) diabetes mellitus and abnormal glucose tolerance–a population-based twin study. Diabetologia 1999, 42(2):139-45.
• [5]Meigs JB, Cupples LA, Wilson PW: Parental transmission of type 2 diabetes: the Framingham Offspring Study. Diabetes 2000, 49(12):2201-7.
• [6]Pierce M, Keen H, Bradley C: Risk of diabetes in offspring of parents with non-insulin-dependent diabetes. Diabet Med 1995, 12(1):6-13.
• [7]Grarup N, Sandholt C, Hansen T, Pedersen O: Genetic susceptibility to type 2 diabetes and obesity: from genome-wide association studies to rare variants and beyond. Diabetologia 2014, 57(8):1528-41.
• [8]Drong AW, Lindgren CM, McCarthy MI: The genetic and epigenetic basis of type 2 diabetes and obesity. Clin Pharmacol Ther 2012, 92(6):707-15.
• [9]Heni M, Ketterer C, Wagner R, Linder K, Böhm A, Herzberg-Schäfer SA, et al.: Polymorphism rs11085226 in the gene encoding polypyrimidine tract-binding protein 1 negatively affects glucose-stimulated insulin secretion. PLoS One 2012, 7(10):e46154.
• [10]Oh YL, Hahm B, Kim YK, Lee HK, Lee JW, Song O, et al.: Determination of functional domains in polypyrimidine-tract-binding protein. Biochem J 1998, 331(Pt 1):169-75.
• [11]Spellman R, Rideau A, Matlin A, Gooding C, Robinson F, McGlincy N, et al.: Regulation of alternative splicing by PTB and associated factors. Biochem Soc Trans 2005, 33(Pt 3):457-60.
• [12]Sawicka K, Bushell M, Spriggs Keith A, Willis Anne E: Polypyrimidine-tract-binding protein: a multifunctional RNA-binding protein. Biochem Soc Trans 2008, 36(4):641.
• [13]Auweter SD, Allain FHT: Structure-function relationships of the polypyrimidine tract binding protein. Cell Mol Life Sci 2008, 65(4):516-27.
• [14]Tillmar L: Control of Insulin mRNA Stability in Rat Pancreatic Islets: Regulatory role of a 3’-untranslated region pyrimidine-rich sequence. J Biol Chem 2001, 277(2):1099-106.
• [15]Knoch K-P, Bergert H, Borgonovo B, Saeger H-D, Altkrüger A, Verkade P, et al.: Polypyrimidine tract-binding protein promotes insulin secretory granule biogenesis. Nat Cell Biol 2004, 6(3):8-214.
• [16]Knoch K-P, Meisterfeld R, Kersting S, Bergert H, Altkrüger A, Wegbrod C, et al.: cAMP-dependent phosphorylation of PTB1 promotes the expression of insulin secretory granule proteins in β cells. Cell Metab 2006, 3(2):123-34.
• [17]Süss C, Czupalla C, Winter C, Pursche T, Knoch K-P, Schroeder M, et al.: Rapid Changes of mRNA-binding Protein Levels following Glucose and 3-Isobutyl-1-methylxanthine Stimulation of Insulinoma INS-1 Cells. Mol Cell Proteomics 2009, 8(3):393-408.
• [18]Jang SK, Wimmer E: Cap-independent translation of encephalomyocarditis virus RNA: structural elements of the internal ribosomal entry site and involvement of a cellular 57-kD RNA-binding protein. Genes Dev 1990, 4(9):1560-72.
• [19]Cote CA, Gautreau D, Denegre JM, Kress TL, Terry NA, Mowry KL: A xenopus protein related to hnRNP I has a role in cytoplasmic RNA localization. Mol Cell 1999, 4(3):431-7.
• [20]Song Y: Evidence for an RNA chaperone function of polypyrimidine tract-binding protein in picornavirus translation. RNA 2005, 11(12):1809-24.
• [21]Fred RG, Bang-Berthelsen CH, Mandrup-Poulsen T, Grunnet LG, Welsh N: High glucose suppresses human islet insulin biosynthesis by inducing miR-133a leading to decreased polypyrimidine tract binding protein-expression. PLoS One 2010, 5(5):e10843.
• [22]Ehehalt F, Knoch K, Erdmann K, Krautz C, Jäger M, Steffen A, et al.: Impaired insulin turnover in islets from type 2 diabetic patients. Islets 2010, 2(1):30-6.
• [23]Scott RA, Lagou V, Welch RP, Wheeler E, Montasser ME, Luan J, et al.: Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet 2012, 44(9):991-1005.
• [24]Gibbs RA, Belmont JW, Hardenbol P, Willis TD, Yu F, Yang H, et al.: The International HapMap Project. Nature 2003, 426(6968):789-96.
• [25]Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998, 15(7):539-53.
• [26]Glümer C, Jørgensen T, Borch-Johnsen K: Prevalences of diabetes and impaired glucose regulation in a Danish population: the Inter99 study. Diabetes Care 2003, 26(8):2335-40.
• [27]Andersen L, Dinesen B, Jorgensen PN, Poulsen F, Roder ME: Enzyme immunoassay for intact human insulin in serum or plasma. Clin Chem 1993, 39(4):578-82.
• [28]Heding LG: Specific and direct radioimmunoassay for human proinsulin in serum. Diabetologia 1977, 13(5):467-74.
• [29]Faber OK, Markussen J, Naithani VK, Binder C: Production of antisera to synthetic benzyloxycarbonyl-C-peptide of human proinsulin. Hoppe Seylers Z Physiol Chem 1976, 357(6):751-7.
• [30]Faber OK, Binder C, Markussen J, Heding LG, Naithani VK, Kuzuya H, et al.: Characterization of seven C-peptide antisera. Diabetes 1978, 27(Suppl 1):170-7.
• [31]Almasy L, Blangero J: Multipoint quantitative-trait linkage analysis in general pedigrees. Am J Hum Genet 1998, 62(5):1198-211.
• [32]Phillips DIW, Clark PM, Hales CN, Osmond C: Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabet Med 1994, 11(3):286-92.
• [33]Sluiter WJ, Erkelens DW, Reitsma WD, Doorenbos H: Glucose tolerance and insulin release, a mathematical approach I: assay of the beta-cell response after oral glucose loading. Diabetes 1976, 25(4):241-4.
• [34]Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28(7):412-9.
• [35]Hansen T, Drivsholm T, Urhammer SA, Palacios RT, Vølund A, Borch-Johnsen K, et al.: The BIGTT test: a novel test for simultaneous measurement of pancreatic β-cell function, insulin sensitivity, and glucose tolerance. Diabetes Care 2007, 30(2):257-62.
• [36]Matsuda M, DeFronzo RA: Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999, 22(9):1462-70.
• [37]Pacini G, Bergman RN: MINMOD: a computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test. Comput Methods Programs Biomed 1986, 23(2):113-22.
• [38]Steil GM, Volund A, Kahn SE, Bergman RN: Reduced sample number for calculation of insulin sensitivity and glucose effectiveness from the minimal model: suitability for use in population studies. Diabetes 1993, 42(2):250-6.
• [39]Steil GM, Murray J, Bergman RN, Buchanan TA: Repeatability of insulin sensitivity and glucose effectiveness from the minimal model: implications for study design. Diabetes 1994, 43(11):1365-71.
• [40]Ferrari P, Alleman Y, Shaw S, Riesen W, Weidmann P: Reproducibility of insulin sensitivity measured by the minimal model method. Diabetologia 1991, 34(7):527-30.
• [41]Yang YJ, Youn JH, Bergman RN: Modified protocols improve insulin sensitivity estimation using the minimal model. Am J Physiol 1987, 253(6 Pt 1):E595-602.
• [42]Hovorka R, Koukkou E, Southerden D, Powrie JK, Young MA: Measuring prehepatic insulin secretion using a population model of C-peptide kinetics: accuracy and required sampling schedule. Diabetologia 1998, 41(5):548-54.
• [43]Kjems LL, Holst JJ, Volund A, Madsbad S: The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 2003, 52(2):380-6.
• [44]Bergman RN, Phillips LS, Cobelli C: Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 1981, 68(6):1456-67.
• [45]Bergman RN: Lilly lecture 1989: toward physiological understanding of glucose tolerance: minimal-model approach. Diabetes 1989, 38(12):1512-27.
• [46]DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986, 7(3):177-88.
• [47]Prokopenko I, Poon W, Mägi R, Prasad BR, Salehi SA, Almgren P, et al.: A central role for GRB10 in regulation of islet function in man. PLoS Genet 2014, 10(4):e1004235.
• [48]Mahajan A, Go MJ, Zhang W, Below JE, et al.: Replication DIG, Meta-analysis C, Asian Genetic Epidemiology Network Type 2 Diabetes C, South Asian Type 2 Diabetes C, Mexican American Type 2 Diabetes C, Type 2 Diabetes Genetic Exploration by Next-generation sequencing in multi-Ethnic Samples C: Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet 2014, 46(3):234-44.
• [49]Pérez I, McAfee JG, Patton JG: Multiple RRMs contribute to RNA binding specificity and affinity for polypyrimidine tract binding protein†. Biochemistry 1997, 36(39):11881-90.